Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Maryam Abbaspour Babaei, Behnam Kamalidehghan, Mohammad Saleem, Hasniza Zaman Huri & Fatemeh Ahmadipour. (2016) Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells. Drug Design, Development and Therapy 10, pages 2443-2459.
Read now
Read now
Muneera Al-Hussaini & John F DiPersio. (2014) Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic. Expert Review of Hematology 7:4, pages 439-464.
Read now
Read now
Michel Arock & Peter Valent. (2010) Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Review of Hematology 3:4, pages 497-516.
Read now
Read now
Shinsuke Suzuki, Kimiharu Uozumi, Shuichi Hanada, Xiao-Yan Lin, Nobuhito Ohno, Yoshifusa Takatsuka, Syogo Takeuchi, Satsuki Owatari, Taketsugu Takeshita & Terukatsu Arima. (2003) A Novel c-kit Positive Biphenotypic Acute Leukemia Cell Line, TMBL-1, Carrying a p53 Point Mutation. Leukemia & Lymphoma 44:5, pages 849-857.
Read now
Read now
Zhi-Qiang Ning, Jin Li & Robert J. Arceci. (2001) Activating Mutations of c-Kit at Codon 816 Confer Drug Resistance in Human Leukemia Cells. Leukemia & Lymphoma 41:5-6, pages 513-522.
Read now
Read now
Sarah Moore & Louise A. McDiarmid. (2000) Stem Cell Factor and Chronic Myeloid Leukemia CD34+ Cells. Leukemia & Lymphoma 38:3-4, pages 211-220.
Read now
Read now
Articles from other publishers (18)
Angélica Sandoval-Pérez, Beth Apsel Winger & Matthew P. Jacobson. (2022) Assessing the Activation of Tyrosine Kinase KIT through Free Energy Calculations. Journal of Chemical Theory and Computation 18:10, pages 6251-6258.
Crossref
Crossref
Glenn Cruse, Dean D. Metcalfe & Ana Olivera. (2014) Functional Deregulation of KIT. Immunology and Allergy Clinics of North America 34:2, pages 219-237.
Crossref
Crossref
Friedrich Stölzel, Christine Steudel, Uta Oelschlägel, Brigitte Mohr, Sina Koch, Gerhard Ehninger & Christian Thiede. (2010) Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells. Annals of Hematology 89:7, pages 653-662.
Crossref
Crossref
Irene Ruano, Ricardo Gargini & Marta Izquierdo. (2010) Combination of KIT gene silencing and tocopherol succinate may offer improved therapeutic approaches for human mastocytosis. British Journal of Haematology 148:1, pages 59-68.
Crossref
Crossref
Rob P. Coppes, Annemieke van der Goot & Isabelle M.A. Lombaert. (2009) Stem Cell Therapy to Reduce Radiation-Induced Normal Tissue Damage. Seminars in Radiation Oncology 19:2, pages 112-121.
Crossref
Crossref
Yashoda Sharma, Clinton M. Astle & David E. Harrison. (2007) Heterozygous Kit Mutants with Little or No Apparent Anemia Exhibit Large Defects in Overall Hematopoietic Stem Cell Function. Experimental Hematology 35:2, pages 214.e1-214.e9.
Crossref
Crossref
Tanya JelacicDiana Linnekin. (2005) PKCδ plays opposite roles in growth mediated by wild-type Kit and an oncogenic Kit mutant. Blood 105:5, pages 1923-1929.
Crossref
Crossref
Johan Lennartsson, Tanya Jelacic, Diana Linnekin & R. Shivakrupa. (2009) Normal and Oncogenic Forms of the Receptor Tyrosine Kinase Kit. STEM CELLS 23:1, pages 16-43.
Crossref
Crossref
Rowan Foster, Renate Griffith, Petranel Ferrao & Leonie Ashman. (2004) Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase. Journal of Molecular Graphics and Modelling 23:2, pages 139-152.
Crossref
Crossref
Ewa WandziochCharlotte E. EdlingRuth H. PalmerLeif CarlssonBengt Hallberg. (2004) Activation of the MAP kinase pathway by c-Kit is PI-3 kinase dependent in hematopoietic progenitor/stem cell lines. Blood 104:1, pages 51-57.
Crossref
Crossref
Vinod A. Pullarkat, Carlos Bueso‐Ramos, Raymond Lai, Steven Kroft, Carla S. Wilson, Sheeja T. Pullarkat, Xiangdong Bu, Maung Thein, M. Lee & Russell K. Brynes. (2003)
Systemic mastocytosis with associated clonal hematological non‐mast‐cell lineage disease: Analysis of clinicopathologic features and activating
c‐kit
mutations
. American Journal of Hematology 73:1, pages 12-17.
Crossref
Crossref
Jennifer Reed, Abderrahman Ouban, Frank K. Schickor, Patrick Muraca, Timothy Yeatman & Domenico Coppola. (2002) Immunohistochemical Staining for c-Kit (CD117) Is a Rare Event in Human Colorectal Carcinoma. Clinical Colorectal Cancer 2:2, pages 119-122.
Crossref
Crossref
Naotomo Kambe & Yoshiki Miyachi. (2014) A Possible Mechanism of Mast Cell Proliferation in Mastocytosis. The Journal of Dermatology 29:1, pages 1-9.
Crossref
Crossref
Zhi-Qiang Ning, Jin Li, Myc McGuinness & Robert J Arceci. (2001) STAT3 activation is required for Asp816 mutant c-Kit induced tumorigenicity. Oncogene 20:33, pages 4528-4536.
Crossref
Crossref
Zhi-Qiang NingJin LiRobert J. Arceci. (2001) Signal transducer and activator of transcription 3 activation is required for Asp816 mutant c-Kit–mediated cytokine-independent survival and proliferation in human leukemia cells. Blood 97:11, pages 3559-3567.
Crossref
Crossref
K. Hartmann & B.M. Henz. (2001) Mastocytosis: recent advances in defining the disease. British Journal of Dermatology 144:4, pages 682-695.
Crossref
Crossref
Karin Hartmann & Dean D. Metcalfe. (2000) PEDIATRIC MASTOCYTOSIS. Hematology/Oncology Clinics of North America 14:3, pages 625-640.
Crossref
Crossref
Leonie K Ashman. (1999) The biology of stem cell factor and its receptor C-kit. The International Journal of Biochemistry & Cell Biology 31:10, pages 1037-1051.
Crossref
Crossref